Objective:

To describe a rare case of acute vulvar mucocutaneous reaction following FOLFOX chemotherapy in a patient with rectal adenocarcinoma.

Approach:

Key Findings:

• Vulvar mucocutaneous reactions during fluoropyrimidine-based chemotherapy are extremely rare.
• The case highlights a potential gender disparity in the incidence and severity of 5-FU-induced mucosal toxicity.
• Omission of the 5-FU bolus preserved treatment efficacy while preventing recurrence of this rare toxicity.

Interpretation:

Limitations:

• The rarity of vulvar mucositis may lead to underdiagnosis or underreporting.
• Limited generalizability due to the single case report.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.